Illumina

company

About

Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.

  • 5001 - 10000

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$750M
Industries
Biotechnology,Genetics,Health Care,Medical
Founded date
Jan 1, 1998
Number Of Employee
5001 - 10000
Operating Status
Active
Investor Type
Accelerate

Illumina is an innovative technology and revolutionary assays aiming the analyze genetic variation and function.

These studies will help make the realization of personalized medicine possible. With such rapid advances in technology taking place, it is mission-critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. As a company that places a high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, they strive to meet this challenge. Illumina's innovative, array-based solutions for DNA, RNA, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.

David R. Walt, Satnam Alag, Larry Bock, and John Stuelpnagel co-founded Illumina in San Diego, California in 1998.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$778M
Illumina has raised a total of $778M in funding over 2 rounds. Their latest funding was raised on Jan 4, 2023 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 4, 2023 Post-IPO Debt $750M 1 Bank of America Detail
Jan 10, 2000 Series Unknown $28M 1 Detail

Investments

Number of Investments
Number of Lead Investments
7
3
Illumina has made 7 investments. Their most recent investment was on Sep 1, 2021, when SomaLogic raised $375M.
Date Company Name
Round Money Raised Industry Lead Investor
Sep 1, 2021 SomaLogic
Post-IPO Equity $375M Biotechnology
Mar 1, 2018 Helix
Series B $200M Big Data
Aug 15, 2015 Helix
Series A $100M Big Data Yes
Jun 9, 2015 Twist Bioscience
Series C $37M Biotechnology Yes
Series Unknown £25M Biopharma

Investors

Number of Lead Investors
Number of Investors
1
2
Illumina is funded by 2 investors. Bank of America and ARCH Venture Partners are the most recent investors.
Investor Name Lead Investor Funding Round
Bank of America Yes Post-IPO Debt
ARCH Venture Partners Series Unknown